Alpha Mark Advisors, LLC Mirati Therapeutics, Inc. Transaction History

Alpha Mark Advisors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Apr 24, 2020	SELL	$69.78 - $116.21 $27,912 - $46,484	-400 Closed	0 $0
Q3 2018 Nov 05, 2018	SELL	$47.1 - $62.7 $11,775 - $15,675	-250 Reduced 38.46%	400 $19,000
Q1 2018 May 09, 2018	SELL	$17.2 - $34.95 $10,320 - $20,970	-600 Reduced 48.0%	650 $20,000
Q4 2017 Feb 09, 2018	BUY	$12.65 - $19.0 $3,162 - $4,750	250 Added 25.0%	1,250 $23,000
Q3 2017 Nov 02, 2017	BUY	$4.7 - $11.7 $4,700 - $11,700	1,000	1,000 $12,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Alpha Mark Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Mark Advisors, LLC with notifications on news.